Details of the Drug Formulations

General Information of Drug (ID: DMS2J0Z)

• Drug Name: Pexidartinib Drug Info
• Synonyms: PLX-3397

Indication

Disease Entry	ICD 11	Status	REF
Tenosynovial giant cell tumour	2F7B	Approved	[1]
Alzheimer disease	8A20	Phase 3	[2]
Pigmented villonodular synovitis	FA27.1	Phase 3	[3]
Neurofibromatosis type 1	LD2D.10	Phase 1/2	[4]

• Cross-matching ID:
  PubChem CID: 25151352
  ChEBI ID: CHEBI:145373
  CAS Number: 1029044-16-3
  TTD ID: D09TAB
  ACDINA ID: D01339

Full List of Drug Formulations Containing This Drug

Pexidartinib 200 mg capsule

Company	Formulation ID	FDA Description
Daiichi Sankyo	F23256	Poloxamer 407; Mannitol; Crospovidone; Magnesium Stearate; Capsule Shell: Hypromellose; Titanium Dioxide; Black Iron Oxide; Yellow Iron Oxide

References

• [1] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019
• [2] ClinicalTrials.gov (NCT02371369) PLX3397 Phase 3 Study for Pigmented Villonodular Synovitis (PVNS) or Giant Cell Tumor of the Tendon Sheath (GCT-TS). U.S. National Institutes of Health.
• [3] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [4] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)